ACTRN12623000653662
Not yet recruiting
未知
A registry study to prospectively describe the proportion of advanced cancer patients being treated with immunotherapy who remain progression free at 6 months after local treatment of up to five sites of oligoprogressive disease
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Bendigo Health
- Enrollment
- 33
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Patients with histologically proven advanced cancer receiving immunotherapy. Advanced cancer will include any unresectable locally advance or metastatic cancer, primary tumour agnostic. Accepted tumour types will include melanoma, lung cancer, renal cell carcinoma, urothelial cancer, head and neck cancers, and deficient MMR cancer of any primary.
- •2\. On systemic immunotherapy, either alone or in combination the chemotherapy or another systemic treatment.
- •3\. Must have evidence of extracranial metastatic disease with or without intracranial metastases.
- •4\. Clinically or radiologically stable or responding disease to immunotherapy for a period of at least 12 weeks prior to study entry with ongoing clinical benefit as deemed by treating clinician.
- •5\. Evidence of isolated progression in 1\-5 lesions amenable to local treatment.
- •6\. Planned local treatment to sites of oligoprogression which can include surgery and/or radiotherapy.
- •7\. Baseline staging either via CT or PET/CT needs to be obtained within 4 weeks of commencement of local therapy. An MRI brain will be required for local therapy of oligoprogressive brain metastases
Exclusion Criteria
- •1\. Pregnancy or lactation at the time of study entry
- •2\. Primary brain tumours
- •3\. Evidence of leptomeningeal disease
- •4\. Evidence of malignant spinal cord compression
- •5\. Contraindication to radiotherapy and/or surgery as local therapy
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
To investigate the types of abnormal breathing patterns in patients with Motor neurone disease (MND) and to assess the usefulness of an 'intelligent' respiratory support device in patients who develop respiratory failureACTRN12614000794606Vinod Aiyappan40
Not yet recruiting
Not Applicable
A study to measure the Peg-Asparaginase (a chemotherapy medicine) drug levels in the body and observe and record allergies after its use in children receiving treatment for acute lymphoblastic leukemia (a type of blood cancer).Health Condition 1: C910- Acute lymphoblastic leukemia [ALL]CTRI/2024/03/063700Dr Chetan Dhamne
Not yet recruiting
Not Applicable
Prospective observation test to evaluate the accuracy by measuring the ovulation cycle of a bodily fluid analyzer (smart ovulation test O'View-W) using saliva and measuring the ovulation cycle by comparing it with the hospital vaginal ultrasound resultKCT0005700Korea Medical Device Development Fund85
Not yet recruiting
Not Applicable
A prospective observational study to evaluate the relationship between adherence to anti-influenza medication and effectiveness in pediatric influenza patientsInfluenza virus infectionJPRN-UMIN000053258Shionogi & Co., Ltd.3,000
Recruiting
Not Applicable
A study to look for the usefulness of BAL test in blood cancer patients with pneumonia.CTRI/2018/10/016073Tata Memorial Centre Research Administrative Council